Table 1 Patients characteristics
N. Patients | 22 |
Median age, years (range) | 48.9 (31–70) |
Progressive disease at study entry | |
No | 8 |
Yes | 14 |
Progressive disease to Her combination | 7 |
Progressive disease to Her alone | 4 |
Progressive disease to non Her containing therapy* | 3 |
Number of sites | |
1 | 1 |
2 | 9 |
≥ 3 | 12 |
Tumor sites | |
Lung | 5 |
Liver | 14 |
Bone | 12 |
Lymphnodes | 8 |
CNS | 9 |
Other | 10 |
Previous treatment with Herceptin alone | 1 |
Previous treatment with Herceptin in combination | 16 |
1 line | 8 |
2 lines | 4 |
3 lines | 4 |
Previous treatment with Herceptin alone and Herceptin in combination | 5 |
2 lines | 4 |
3 lines | 1 |
Herceptin + Vinorelbine | 11 |
Herceptin + Taxanes | 15 |
Herceptin + Others | 5 |
ER and PgR negative | 15 |
ER and/or PgR positive | 7 |
Ki 67 | |
<20% | 1 |
≥20% | 12 |
Unknown | 9 |
Her2/Neu overexpression | |
2+ | 1 |
3+ | 21 |